Monitoring Drug-Induced γH2AX as a Pharmacodynamic Biomarker in Individual Circulating Tumor Cells

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Clinical Cancer Research

• Publication date

  2010-01-26

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-09-2799PMID 20103672PMCID PMC2818670
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Circulating Tumor Cells in Patients with Castration-Resistant Prostate Cancer Baseline Values and Correlation with Prognostic Factors

  2009cited by this paper
• Anti-Epithelial Cell Adhesion Molecule Antibodies and the Detection of Circulating Normal-Like Breast Tumor Cells

  2009cited by this paper
• Gene expression of circulating tumour cells and its correlation with tumour stage in breast cancer patients

  2009cited by this paper
• HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer

  2009cited by this paper
• Gamma-H2AX - a novel biomarker for DNA double-strand breaks.

  2008cited by this paper
• Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.

  2008cited by this paper
• Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase

  2008cited by this paper
• Relationship Between Induction of Phosphorylated H2AX and Survival in Breast Cancer Cells Exposed to 111In-DTPA-hEGF

  2008cited by this paper
• γ-H2AX - A Novel Biomarker for DNA Double-strand Breaks

  2008cited by this paper
• Is There a Role for Circulating Tumor Cells in the Management of Breast Cancer?

  2008cited by this paper
• Detection of mutations in EGFR in circulating lung-cancer cells.

  2008cited by this paper
• Transcription-coupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex.

  2008cited by this paper
• Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy.

  2008cited by this paper
• The Prognostic Implications of Circulating Tumor Cells in Patients with Breast Cancer

  2008cited by this paper
• Circulating Tumor Cells and Bone Marrow Micrometastasis

  2008cited by this paper
• Evidence of in vivo efficacy for the indenoisoquinolines linked with pharmacodynamic markers for γH2AX

  2007cited by this paper
• Circulating Tumor Cell Analysis in Patients with Progressive Castration-Resistant Prostate Cancer

  2007cited by this paper
• Cytometry of ATM activation and histone H2AX phosphorylation to estimate extent of DNA damage induced by exogenous agents

  2007cited by this paper
• Detection of Circulating Tumor Cells in Peripheral Blood of Patients with Metastatic Breast Cancer: A Validation Study of the CellSearch System

  2007cited by this paper
• American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.

  2007cited by this paper
• American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.

  2007cited by this paper
• Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters

  2007cited by this paper
• An optimized method for detecting gamma-H2AX in blood cells reveals a significant interindividual variation in the gamma-H2AX response among humans

  2007cited by this paper
• Development and validation of a quantitative assay for γH2AX in needle biopsies using topoisomerase I inhibitors

  2007cited by this paper
• Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation.

  2006cited by this paper
• Circulating Tumor Cells at Each Follow-up Time Point during Therapy of Metastatic Breast Cancer Patients Predict Progression-Free and Overall Survival

  2006cited by this paper
• Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas.

  2006cited by this paper
• Topoisomerase I inhibitors: camptothecins and beyond

  2006cited by this paper
• ATM signaling and genomic stability in response to DNA damage.

  2005cited by this paper
• gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair.

  2005cited by this paper
• Global gene expression profiling of circulating tumor cells.

  2005cited by this paper
• γ-H2AX Dephosphorylation by Protein Phosphatase 2A Facilitates DNA Double-Strand Break Repair

  2005cited by this paper
• Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer.

  2005influential reference
• Circulating Tumor Cells in Patients with Breast Cancer Dormancy

  2004cited by this paper
• Circulating tumor cells, disease progression, and survival in metastatic breast cancer.

  2004cited by this paper
• HER-2 gene amplification can be acquired as breast cancer progresses.

  2004cited by this paper
• Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross‐linking agent cisplatin

  2004cited by this paper
• Tumor Cells Circulate in the Peripheral Blood of All Major Carcinomas but not in Healthy Subjects or Patients With Nonmalignant Diseases

  2004cited by this paper
• Histone H2A variants H2AX and H2AZ.

  2002cited by this paper
• Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells.

  2001cited by this paper
• Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.

  2001cited by this paper
• A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage.

  2000cited by this paper
• Conversion of Topoisomerase I Cleavage Complexes on the Leading Strand of Ribosomal DNA into 5′-Phosphorylated DNA Double-Strand Breaks by Replication Runoff

  2000cited by this paper
• An overview of cyclophosphamide development and clinical applications.

  1999cited by this paper
• An overview of cyclophosphamide development and clinical applications.

  1999cited by this paper
• The comet assay in clinical practice.

  1999cited by this paper
• Statistical Methods

  1959cited by this paper

• Enhancing the therapeutic potential of plumbagin in breast cancer via advanced nanomedicine approaches

  2026cites this paper
• Mass cytometric detection of homologous recombination proficiency in circulating tumor cells to predict chemoresistance of metastatic breast cancer patients

  2025cites this paper
• Quantification of Unencapsulated Drug in Target Tissues Demonstrates Pharmacological Properties and Therapeutic Effects of Liposomal Topotecan (FF-10850)

  2024cites this paper
• Hydrogel Applications in the Diagnosis and Treatment of Glioblastoma.

  2024cites this paper
• DNA double-strand break repair capacity and its pathway gene variants predict the risk and prognosis of lung cancer.

  2024cites this paper
• A multiparameter liquid biopsy approach allows to track melanoma dynamics and identify early treatment resistance

  2024cites this paper
• Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors

  2023cites this paper
• Investigating the Retained Inhibitory Effect of Cobimetinib against p.P124L Mutated MEK1: A Combined Liquid Biopsy and in Silico Approach

  2022cites this paper
• Bio-inspirited Three-Dimensional Hierarchical Micro/Nano-Structured Microdevice for Enhanced Capture and Effective Release of Circulating Tumor Cells

  2022cites this paper
• Circulating Tumor Cells in Breast Cancer Patients: A Balancing Act between Stemness, EMT Features and DNA Damage Responses

  2022cites this paper
• Methods for the detection of DNA damage

  2021cites this paper
• Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability

  2021cites this paper
• Evaluation of DNA double-strand break repair capacity in human cells: Critical overview of current functional methods.

  2021cites this paper
• Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status

  2021influential citation
• A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies

  2021cites this paper
• Monitoring DNA Damage and Repair in Peripheral Blood Mononuclear Cells of Lung Cancer Radiotherapy Patients

  2020cites this paper
• Intravenous 5-fluoro-2′-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors

  2020cites this paper
• KAT8/MOF-Mediated Anti-Cancer Mechanism of Gemcitabine in Human Bladder Cancer Cells

  2020cites this paper
• Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers

  2019cites this paper
• Drug Design Targeting T-Cell Factor (TCF)-Driven Epithelial-Mesenchymal Transition (EMT) as a Therapeutic Strategy for Colorectal Cancer.

  2019cites this paper
• Clinical Applications of Circulating Tumor Cells in Breast Cancer.

  2019cites this paper
• Recent advances in microfluidic methods in cancer liquid biopsy.

  2019cites this paper
• Spontaneous γH2AX foci in human dermal fibroblasts in relation to proliferation activity and aging

  2019cites this paper
• Novel approaches in cancer management with circulating tumor cell clusters

  2019cites this paper
• Implementing Liquid Biopsies in Clinical Trials: State of Affairs, Opportunities, and Challenges

  2018cites this paper
• Change in Topoisomerase 1–Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol

  2018cites this paper
• Clinical applications of the CellSearch platform in cancer patients.

  2018cites this paper
• Circulating tumor cells in breast cancer patients

  2017cites this paper
• Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.

  2017cites this paper
• The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.

  2017cites this paper
• Biomarkers for early diagnosis, prognosis, prediction, and recurrence monitoring of non-small cell lung cancer

  2017cites this paper
• Bridging Plant and Human Radiation Response and DNA Repair through an In Silico Approach

  2017cites this paper
• Antibody-independent capture of circulating tumor cells of non-epithelial origin with the ApoStream® system

  2017cites this paper
• 3D Models of the NCI60 Cell Lines for Screening Oncology Compounds

  2017cites this paper
• Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy

  2017cites this paper
• CTCs for Biomarker and Companion Diagnostic Development

  2016cites this paper
• Randomized phase II trial of cyclophosphamide and the oral poly (ADP-ribose) polymerase inhibitor veliparib in patients with recurrent, advanced triple-negative breast cancer

  2016cites this paper
• Progress on Molecular Mechanism of Phosphorylation/Dephosphorylation and Detection Technology of γH2AX

  2016cites this paper
• Exploiting synthetic lethality in ovarian cancer

  2016cites this paper
• Circulating Tumor Cells (Liquid Tumor Biopsy) in Hepatocellular Carcinoma: Biology, Methodologies, and Clinical Implications

  2016cites this paper
• TEMPORARY REMOVAL: Strategic Considerations for Achieving Consistent Performance of Transferred Assays in the Research Community

  2016cites this paper
• CELLSEARCH® Instrument, Features, and Usage

  2016cites this paper
• Promise and limits of the CellSearch platform for evaluating pharmacodynamics in circulating tumor cells.

  2016cites this paper
• Circulating Tumor Cells.

  2016cites this paper
• The development of biomarkers to reduce attrition rate in drug discovery focused on oncology and central nervous system

  2016cites this paper
• The root causes of pharmacodynamic assay failure.

  2016cites this paper
• Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors

  2016cites this paper
• DNA Damage of Glioblastoma Multiform Cells Induced by Beta Radiation of Iodine-131 in The Presence or Absence of Topotecan: A Picogreen and Colonogenic Assay

  2015cites this paper
• Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents

  2015cites this paper
• DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity.

  2015cites this paper
• Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer

  2015cites this paper
• γH2AX expression in cytological specimens as a biomarker of response to radiotherapy in solid malignancies

  2015cites this paper
• Circulating Tumor Cells: A Multifunctional Biomarker

  2014cites this paper
• Mobilization of viable tumor cells into the circulation during radiation therapy.

  2014cites this paper
• The promise of circulating tumor cell analysis in cancer management

  2014cites this paper
• Physical biology in cancer. 2. The physical biology of circulating tumor cells.

  2014cites this paper
• Protracted dosing of the lipophilic camptothecin analogue AR-67 in non-small cell lung cancer xenografts and humans

  2014cites this paper
• Molecular analysis of circulating tumour cells—biology and biomarkers

  2014cites this paper
• Implementation of Validated Pharmacodynamic Assays in Multiple Laboratories: Challenges, Successes, and Limitations

  2014cites this paper
• Translational research in oncology—10 years of progress and future prospects

  2014cites this paper
• H2AX a Promising Biomarker for Lung Cancer: A Review

  2013cites this paper
• Can γH2AX be used to personalise cancer treatment?

  2013cites this paper
• Rare cell isolation and profiling on a hybrid magnetic/size-sorting chip.

  2013cites this paper
• Cancer Therapy : Clinical gH 2 AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents : Results from 2 Phase I Clinical Trials of SJG-136 ( SG 2000 )

  2013cites this paper
• Micro and nanotechnology for cancer treatment

  2013cites this paper
• Progress in Using Circulating Tumor Cell Information to Improve Metastatic Breast Cancer Therapy

  2013cites this paper
• Customizing CellSearch platform

  2013cites this paper
• PRECLINICAL AND CLINICAL DEVELOPMENT OF THE LIPOPHILIC CAMPTOTHECIN ANALOGUE AR-67

  2013cites this paper
• Development and Validation of an Immunoassay for Quantification of Topoisomerase I in Solid Tumor Tissues

  2012cites this paper
• A Phase I Study of Veliparib in Combination with Metronomic Cyclophosphamide in Adults with Refractory Solid Tumors and Lymphomas

  2012cites this paper
• Targeted therapy for triple‐negative breast cancer: Where are we?

  2012cites this paper
• Measurement of H2AX Phosphorylation as a Marker of Ionizing Radiation Induced Cell Damage

  2012cites this paper
• Targeting Homologous Recombination Repair in Cancer

  2012cites this paper
• The potential of the PARP-1 inhibitor, AGO14699, in human cancers defective in homologous recombination DNA repair

  2012cites this paper
• γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)

  2012cites this paper
• Assessment of γ-H2AX levels in circulating tumor cells from patients receiving chemotherapy

  2012influential citation
• Considerations in the development of circulating tumor cell technology for clinical use

  2012cites this paper
• Pharmacodynamic end points in early phase oncology trials

  2012cites this paper
• γ-H2AX and other histone post-translational modifications in the clinic.

  2012cites this paper
• PARP Inhibitors

  2012cites this paper
• Measurements of the DNA double-strand break response

  2012cites this paper
• Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research.

  2012influential citation
• Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas.

  2011cites this paper
• Circulating tumor cells : approaches to isolation and characterization

  2011cites this paper
• Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells

  2011cites this paper
• Poly(ADP‐Ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic

  2011cites this paper
• Multiple biomarker expression on circulating tumor cells in comparison to tumor tissues from primary and metastatic sites in patients with locally advanced/inflammatory, and stage IV breast cancer, using a novel detection technology

  2011cites this paper
• PARP inhibitor treatment in ovarian and breast cancer.

  2011cites this paper
• Recent developments in the use of γ -H2AX as a quantitative DNA double-strand break biomarker

  2011cites this paper
• Circulating tumor cells: approaches to isolation and characterization

  2011cites this paper
• Circulating Tumor Cells

  2011cites this paper
• A Glimpse of the Future: Where Will New Combinations of Diagnostics and Therapies Take Us?

  2011cites this paper
• Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

  2011cites this paper
• Circulating tumor cells in breast cancer: A tool whose time has come of age

  2011cites this paper
• Neoepitope Expression in Epithelial Cancer : ntification of Apoptosis in Circulating R or Cells by CellSearch Analysis

  2010cites this paper
• one γ H 2 AX and Poly ( ADP-Ribose ) as Clinical rmacodynamic Biomarkers

  2010cites this paper
• Development of a Validated Immunofluorescence Assay for γH2AX as a Pharmacodynamic Marker of Topoisomerase I Inhibitor Activity

  2010influential citation
• Characterization and Significance of Circulating Tumor Cells in Patients Obtained Using a Negative Depletion Technology

  2010cites this paper
• Circulating Tumor Cells, Enumeration and Beyond

  2010cites this paper
• Clinical Cancer esearch cer Therapy : Preclinical elopment of a Validated Immunofluorescence Assay γ H 2 AX as a Pharmacodynamic Marker of R oisomerase I Inhibitor Activity

  2010cites this paper